GTL 001

Drug Profile

GTL 001

Alternative Names: CyAa-HPV-16E7 CyaA-HPV-18E7 vaccine; GTL001; HPV 16E7 HPV 18E7 protein vaccine; HPV 16E7-HPV 18E7; ProCervix

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator GENTICEL
  • Class Papillomavirus vaccines; Protein-vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Oropharyngeal cancer
  • Discontinued Anal cancer; Cancer; Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 13 Dec 2016 Final efficacy and adverse events data from the phase II RHEIA-VAC trial in Cervical cancer released by Genticel
  • 01 Dec 2016 Genticel terminates a phase I trial in Human papillomavirus infections in USA due to lack of efficacy in European Phase II study (Parenteral) (NCT02689726)
  • 01 Oct 2016 Genticel completes the RHEIA-VAC trial in Cervical cancer (Prevention)/Human papillomavirus infections in United Kingdom, Belgium, Finland, France, Germany, Netherlands and Spain (NCT01957878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top